Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients

Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has infected millions, with more than 275,000 fatal cases as of May 8, 2020. Currently, there are no specific COVID-19 therapies. Most patients depend on mechanical ventilation. Current...

Full description

Bibliographic Details
Main Authors: Srinivasa Reddy Bonam, Srini V. Kaveri, Anavaj Sakuntabhai, Laurent Gilardin, Jagadeesh Bayry
Format: Article
Language:English
Published: Elsevier 2020-05-01
Series:Cell Reports Medicine
Subjects:
SARS-CoV-2
COVID-19
cytokine storm syndrome
immunotherapy
cytokines
monoclonal antibody
Online Access:http://www.sciencedirect.com/science/article/pii/S2666379120300215

Internet

http://www.sciencedirect.com/science/article/pii/S2666379120300215

Similar Items